These are heady times for the private equity industry. With interest rates low and doubts swirling about the bull market’s longevity – not to mention dreary returns in the competing hedge fund industry – investors are pouring cash into private equity funds. Indeed, there is more private equity capital to deploy than ever before. According to Preqin, a ... READ MORE >
private equity
Private equity looks for recession-proof deals
These are flush times for American private equity funds. Through November, they have raised more capital than any other fiscal year. But a good portion of that cash has not been put to use – yet. One reason is that many takeover targets have simply become too expensive, a dynamic reflected in the drop in deal activity for 2019. According to RSM Bloomberg, ... READ MORE >
Scrutiny on private equity investment in health care increases
As private equity groups continue to invest in the health care industry, their business practices are falling under increasing scrutiny from lawmakers, researchers and the news media. In 2018, for example, three Yale University researchers released a report that examined how out-of-network billing for emergency care in the United States can lead to ... READ MORE >
For private equity funds, bigger is not always better
The rise of billion-dollar private equity buyout funds reflects the growing demand from large investors willing to write big checks. Interest rates remain historically low and, with additional rate cuts almost certain to come, investors continue to expect high returns. The larger the fund, so the thinking goes, the larger the return. This may not be the ... READ MORE >
Latest C-corporation conversion announcement follows trend with largest alternative asset managers
Carlyle Group LP, among the world's largest private equity firms, is expected to announce it conversion to a C-corporation from a publicly trade partnership during its second-quarter earnings call on July 31. It is the latest alternative asset manager to make the conversion following peers that include Apollo Global Management LLC, Blackstone Group LP, Ares ... READ MORE >
Biotech needs cash in hesitant market
Life science companies require a cash infusion at least twice as big as that of 2018 to fund research and development at a time when investors remain skittish, according to a Bloomberg analysis. The analysis suggests that over 100 biotech companies, including makers of oncology therapies and treatments for other life-threatening conditions, need to raise ... READ MORE >